RiTUXimab 375 mg/m2 Maintenance Therapy-84 day. NCCP National SACT Regimen. HSE.
Regulatory approval published by the Health Service Executive.
Citation
Regulatory approvals
Approved indications from this document for cancer drugs containing at least one biomarker.
| Indication | Statements |
|---|---|
| Maintenance therapy for the treatment of relapsed/refractory follicular CD20 positive, B-cell Non Hodgkin Lymphoma (NHL) in patients who have responded to induction therapy. | 2 |
Therapeutic response
Precision oncology relationships for therapeutic response derived from this document.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| HSE (1) | CD20 + | Non-Hodgkin Lymphoma | Rituximab | |
| HSE (1) | CD20 + | Follicular Lymphoma | Rituximab |